Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.58 |
| ▸ | PPARG | P37231 | 11/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073141 | 0.94 | PPARA (0.56) | PPARAPPARGCYP3A4RXRACYP2C9 | |
| SCHEMBL6073345 | 0.93 | PPARA (0.57) | PPARAPPARGCYP3A4RXRACYP2C9 | |
| SCHEMBL6072992 | 0.93 | PPARA (0.51) | PPARAPPARGCYP3A4RXRACYP2C9 | |
| SCHEMBL6073127 | 0.91 | PPARA (0.52) | PPARAPPARGCYP2C9KCNH2SLC2A1 | |
| SCHEMBL6073204 | 0.90 | PPARA (0.52) | PPARAPPARGCYP3A4RXRAPOLB | |
| SCHEMBL6073133 | 0.89 | PPARG (0.49) | PPARAPPARGCYP3A4RXRAMCHR1 | |
| SCHEMBL6073143 | 0.89 | PPARA (0.47) | PPARAPPARGPOLBCYP2C9KCNH2 | |
| SCHEMBL6073312 | 0.87 | PPARA (0.49) | PPARAPPARGCYP3A4RXRACYP2C9 | |
| SCHEMBL6073111 | 0.85 | PPARA (0.52) | PPARAPPARGCYP2C9KCNH2SLC2A1 | |
| SCHEMBL6073100 | 0.85 | PPARA (0.46) | PPARAPPARGCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006117743-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS ANTIDIABETIC AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2006117743-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS ANTIDIABETIC AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARA 990/4885PPARG 615/4885CYP3A4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.